150 related articles for article (PubMed ID: 32819759)
1. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract][Full Text] [Related]
2. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
3. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
4. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
5. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
8. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
9. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
10. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
[TBL] [Abstract][Full Text] [Related]
11. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing
Reinert CP; Gatidis S; Sekler J; Dittmann H; Pfannenberg C; la Fougère C; Nikolaou K; Forschner A
Cancer Imaging; 2020 Jul; 20(1):44. PubMed ID: 32631431
[TBL] [Abstract][Full Text] [Related]
13. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
14. Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative
de Heer EC; Brouwers AH; Boellaard R; Sluiter WJ; Diercks GFH; Hospers GAP; de Vries EGE; Jalving M
EJNMMI Res; 2018 Nov; 8(1):101. PubMed ID: 30460579
[TBL] [Abstract][Full Text] [Related]
15. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
16. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
20. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]